Premium
Successful treatment with telaprevir‐based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis
Author(s) -
Haseltine E. L.,
Penney M. S.,
George S.,
Kieffer T. L.
Publication year - 2015
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/jvh.12382
Subject(s) - telaprevir , medicine , regimen , gastroenterology , stage (stratigraphy) , fibrosis , liver fibrosis , hepatitis c , hepatitis c virus , immunology , ribavirin , virus , biology , paleontology
Summary Patients infected with hepatitis C virus ( HCV ) have differing levels of liver health when they initiate treatment. We sought to quantify whether liver health improves following successful treatment with telaprevir‐based antiviral regimens. We performed a retrospective analysis of data generated from one P hase 2 and two P hase 3 telaprevir clinical studies. 1208 patients treated with a telaprevir‐based regimen were included in the analysis. Patients were grouped according to their baseline M etavir score ( F 0– F 1, F 2 and F 3– F 4) and whether or not they attained sustained virologic response ( SVR ). Scores from four biomarker tests, F ibro T est, APRI , FIB ‐4 and F orns' S core, were monitored both before and after HCV treatment. All four of these tests differentiated the fibrosis stage as determined by M etavir score at baseline. Consistent with previous studies, patients who attained SVR exhibited significant improvements in scores from each of these tests after treatment. These improvements remained significant even when patients were grouped according to their baseline M etavir score. On average, the scores from different tests exhibited differential improvements following SVR . Improvements in APRI scores corresponded to complete fibrosis regression (i.e. a Metavir stage of F 0‐ F 1). In contrast, improvements in scores from Forns' Score, FIB ‐4 and FibroTest were more modest (i.e. fibrosis regression of less than a M etavir stage). Overall, these results demonstrated that attaining SVR with a telaprevir‐based regimen led to significant improvements in liver health as determined by four biomarker tests. However, not all correlations observed between noninvasive markers and fibrosis stage at baseline hold after SVR is attained.